The Pulse of New York Tech
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions. Founded in 2017, Anaveon is backed by investors that include Novartis Venture Fund and Syncona Partners LLP.
WRITE FOR US
NYC TECH EVENTS
NYC TECH NEWS
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.